Senses Disorder TRIZ Cases

Culturing retinal progenitor cells with sequential Wnt, IGF, and Shh activators to generate mature retinal ganglion cells.

A Crovalimab dosing regimen uses intravenous loading followed by subcutaneous maintenance doses to sustain terminal complement blockade.

Hyaluronic acid and polyoxyethylene stearate solubilize sulfasalazine, avoiding salt-forming complexity while maintaining pH stability.

A graphene-based biointerface absorbs light to generate charge carriers that alter cell membrane potential.

Beta-amino isoquinolinyl amide compounds modulate intracellular kinase activity, addressing receptor desensitization in glaucoma and cancer treatments.

A p38 MAP kinase inhibitor suppresses mitochondrial membrane potential decrease in corneal endothelial cells.

A layered collagen and hydrophilic polymer membrane protects intraocular tissues during surgery.

Phenalkylamine compounds modulate the 5-HT2A receptor to treat psychiatric diseases without hallucinogenic effects.

Parthenolide reduces microtubule detyrosination at axonal tips, overcoming inadequate sensory restoration in central nervous system injuries.

Pyrrolidine and thiazolidine compounds inhibit the DPP-IV enzyme, preventing GLP-1 degradation to increase insulin levels without hypoglycemia risk.

CatCh mutant channelrhodopsin increases calcium permeability and light sensitivity through targeted amino acid mutations.

Novel phenoxymethyl compounds inhibit autotaxin activity to reduce lysophosphatidic acid production.

Ternary polymers solubilize cyclosporin A in water, resolving low solubility and irritation issues found in oily emulsions.

Interfering RNAs silence Frizzled Related Protein-1 mRNA expression to treat glaucoma.

Modified indole derivatives selectively inhibit HIV splicing while minimizing DNA intercalation risks associated with flat structures.

A handheld micro-dosing device delivers precise 1-15 μl liquid formulations to the eye using a collimated stream generated by a piezoelectric actuator.

Single-dose rAAV administration reduces injection frequency and adverse effects while maintaining long-term ocular disease efficacy.

Human immature dental pulp stem cells expressing CD44 and CD13 cross the blood-brain barrier to induce neurogenesis.

PRDX2 and PRDX6 proteins scavenge reactive oxygen species, restoring sperm quality and treating male infertility caused by oxidative stress.

d-MAPPS biologics deliver MSC-derived exosomes to regenerate ocular tissues, reducing reapplication frequency.

Replacing mechanical forces with enzymatic dissociation in a closed biochamber maintains cell viability and yield while removing residual culture components.

4-nitrooxybutan-1-ol alkyl esters lower intraocular pressure via nitric oxide-mediated relaxation, reducing side effects from high conventional drug doses.

Antisense oligonucleotides modulate DMD family polynucleotide expression through targeted hybridization and chemical modifications.

Self-forming liposomes enable topical ranibizumab delivery through the cornea to treat posterior segment eye disorders.

Anti-IL13 antibodies neutralize human IL-13 to resolve inflammation without corticosteroid side effects, improving airway function in asthma.

Soft hydrogel ocular inserts use arylborono crosslinks that hydrolyze in tear fluid, eliminating manual removal and blurred vision.

Partial crosslinking of the amniotic membrane periphery provides structural adhesion without plastic rings, resolving foreign object sensation.

Benzamide derivatives inhibit hydroxysteroid dehydrogenases, resolving the trade-off between inhibitor potency and isoform selectivity.

Altered CD2 domain polypeptides selectively target activated endothelial cells, reducing tumor weight and toxicity while extending circulation time.

Pyridine and pyrazine derivatives restore mutant CFTR channel function, resolving impaired salt transport in cystic fibrosis.

Formula I compounds modulate PI3 kinase activity to treat cancer and autoimmune disorders by ameliorating inflammation.

Phosphonamidate compounds inhibit Bcl proteins to promote apoptosis in senescent cells, reducing tissue damage in osteoarthritis and atherosclerosis.

Novel pyrimidine derivatives inhibit spleen tyrosine kinase activity for pharmaceutical use.

Bicyclic heterocyclic derivatives inhibit protein tyrosine kinases through precise structural substitution.

A 1,2-naphthoquinone derivative activates the NQO1 enzyme to induce exercise imitation effects.

Aminopyrazole derivatives block ischemic cell death pathways to protect organs from tissue damage.

A chemosensory detection system measures T2R and T1R receptor expression to predict individual wine tasting preferences.

Monoclonal antibodies bind HtrA1 serine protease with high affinity to block enzymatic function.

Low molecular compounds address costly, ineffective treatments by targeting multiple hearing loss causes.

End-capped very low molecular weight polymers enable sustained drug release without viscosity-reducing agents.

A novel mitochondrial peptide increases insulin secretion and decreases fat accumulation.

Modified AAV capsids enable covalent conjugation to resolve low functional titer limits in gene therapy production.

Optimized pH and polymer blend in aqueous atropine solution reduces mydriasis while maintaining viscosity stability.

L-Alanyl-L-Glutamine in an isoosmotic solution treats dry eye disease by restoring goblet cell density and corneal barrier function without toxic side effects.

An amphiphilic hydrogel contact lens controls drug release via ionic bonds, reducing initial bursts while maintaining oxygen permeability.

Silk fibroin matrices stabilize fragile proteins and deliver high local concentrations to treat glaucoma without complex external devices.